What sermorelin is

• What sermorelin is and why the 29-residue fragment keeps full GHRH activity
• How the GHRH receptor, the GH pulse, and the IGF-1 axis actually work
• Why preserving pulsatility is the pharmacologic argument over recombinant GH
• How to read the pediatric evidence, the adult studies, and the marketing claims tier by tier
• Where sermorelin stands as a compounded product and under anti-doping rules

1. 01 What sermorelin is The hypothalamic fragment that tells the pituitary to make growth hormone free
2. 02 Chemistry and structure A defined 29-residue fragment that carries the whole GHRH signal paid
3. 03 The GHRH receptor One receptor, a cAMP cascade, and the biology of a single GH pulse paid
4. 04 The GH and IGF-1 axis From a pituitary pulse to IGF-1, and back again through feedback paid
5. 05 Pediatric growth hormone deficiency The approved past: sermorelin’s strongest, and oldest, direct evidence paid
6. 06 Adult use and the evidence The off-label present: real mechanism, small studies, and honest limits paid
7. 07 Compared with other GH secretagogues Sermorelin in a crowded field: analogs, secretagogues, and rhGH paid
8. 08 Dosing and administration How sermorelin is prepared and given, for education only paid
9. 09 Safety and product quality What is reported, what is theoretical, and what is unknown paid
10. 10 Administration and the regulatory landscape A compounded peptide in a shifting regulatory world paid
11. 11 Final exam and certification Pass the final exam to earn your certificate of completion. Exam

Before any detail, hold the whole idea in one sentence. Sermorelin does not add growth hormone to the body. It hands the pituitary the same start signal the hypothalamus uses, and the pituitary releases a pulse of its own GH.

Because the pituitary and its feedback loops stay in charge, the response is expected to be self-limiting: a review of the secretagogue class describes the GH release these drugs promote as pulsatile and subject to negative feedback, which may prevent supratherapeutic GH levels. That single feature, working with the body rather than overriding it, is the thread running through everything else in this course.

The story starts with a tumor. In 1982 Guillemin and colleagues isolated GHRH from a pancreatic tumor that was causing acromegaly, finally naming the long-sought hypothalamic factor that switches on growth hormone.

The key nuance is why the drug left the market. Geref was not withdrawn for reasons of safety or effectiveness, and the FDA formally determined so in 2013. Read the notice itself and it is about generic applications and the Orange Book: the determination will let FDA approve abbreviated new drug applications referring to Geref, and both products stay on the Orange Book list of products discontinued for reasons other than safety or effectiveness. It never mentions compounding. Compounding has its own list, kept in FDA's regulations: drug products withdrawn or removed from the market because they were found unsafe or not effective may not be compounded. Sermorelin is not on that list, which fits the 2013 finding, though no source this course holds says the finding is the reason.

The central pharmacologic argument for sermorelin is a shape, not a size. Natural GH arrives in pulses, and the most reproducible one comes shortly after you fall asleep. Injected recombinant GH bypasses the feedback that shapes those pulses and does not restore them: each injection gives a single high-amplitude surge instead.

Pulsatility is not a cosmetic detail, though the usual reason given for that is a mechanistic expectation rather than a measurement: the gaps between pulses are thought to let receptors reset. What has been measured, in rats, is narrower. The GH response to GHRH was weak during troughs of the GH rhythm because circulating somatostatin antagonised it, and the authors read their results as support for a model in which GHRH and somatostatin are each released steadily, with a superimposed three-to-four-hour rhythmic surge of each.

Sermorelin invites hype, so set the ceiling before the science. The evidence is genuinely uneven: strong where it is old and clinical, and thin exactly where the marketing is loudest.

Keeping these tiers apart is the entire discipline of the course. The pediatric data are genuinely solid, the short-term hormone changes are believable, and the sweeping adult promises rest on extrapolation rather than trials. Confusing one tier for another is exactly how honest education slides into marketing.

A few claims you will meet online, held against the tiers above. Most are not simply false. They are real but modest findings that get rounded up into transformations as they travel from journals to sales pages.

That fourth row is a good example of why tiers beat verdicts. There genuinely are placebo-controlled sleep-laboratory studies here, so "no evidence" would be wrong. But they gave GHRH intravenously over single laboratory nights, the effect reversed direction by sex, and none of them studied the nightly subcutaneous product people actually buy. Real evidence, aimed slightly to the side of the question.

The skill this course builds is reading each claim against its tier. When a source states an exact adult benefit with confidence, that confidence itself is usually the red flag.